Sanjivani Biochem Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.50 M
- Company Age 20 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 3.50 Cr
- Revenue Growth -62.69%
- Profit Growth -44.05%
- Ebitda -56.62%
- Net Worth 26.25%
- Total Assets -38.23%
About Sanjivani Biochem
Sanjivani Biochem Private Limited (SBPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 10 November 2004 and has a history of 20 years and two months. Its registered office is in Ahmedabad, Gujarat, India.
The Corporate was formerly known as Sanjivani Pharma Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹3.50 Cr.
Pankaj Kedia and Neelam Kedia serve as directors at the Company.
Company Details
-
Location
Ahmedabad, Gujarat, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U33110GJ2004PTC045012
-
Company No.
045012
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
10 Nov 2004
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Sanjivani Biochem?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pankaj Kedia
|
Director | 08-Dec-2015 | Current |
|
Neelam Kedia
|
Director | 10-Nov-2004 | Current |
Financial Performance of Sanjivani Biochem.
Sanjivani Biochem Private Limited, for the financial year ended 2024, experienced significant reduction in revenue, with a 62.69% decrease. The company also saw a substantial fall in profitability, with a 44.05% decrease in profit. The company's net worth Soared by an impressive increase of 26.25%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sanjivani Biochem?
In 2024, Sanjivani Biochem had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹35.00 M
₹0
Charges Breakdown by Lending Institutions
- Axis Bank Limited : 3.50 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 24 Jan 2019 | Axis Bank Limited | ₹3.50 Cr | Open |
How Many Employees Work at Sanjivani Biochem?
Unlock and access historical data on people associated with Sanjivani Biochem, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sanjivani Biochem, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sanjivani Biochem's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
